criteria included acute or recent myocardial infarction (MI), left ventricular ejection fraction Ͻ30%, left main or ostial location, major bifurcation disease, chronic total occlusion, and target vessel thrombus. Routine angiographic follow-up was not performed. Planned clinical follow-up is at 1, 6, 12, and 18 months, and annually to 5 years. Results: Patients were predominantly male (62.7%), and 30.0% presented with medically treated diabetes. At baseline, target lesion length was 24.38Ϯ8.21mm and reference vessel diameter was 2.56Ϯ0.40mm. The study met its primary endpoint of 12-month target lesion failure (composite of target vessel related cardiac death/MI and ischemia-driven target lesion revascularization) with a rate of 3.2%, which was not significantly different (pϽ0.001) than a prespecified performance goal of 19.4% (based on historical outcomes with 32mm paclitaxel-eluting stents, the only long drug-eluting stent approved in the US when PLATINUM LL was initiated). At 1-year follow-up, there were 3 instances of target lesion revascularization (3.1%), 1 non-cardiac death, and no cardiac deaths, MIs, or stent thromboses. Two-year clinical follow-up will be reported.
TCT-613

A Prospective Randomized Multi-Center Trial to Assess the EverolimusEluting Stent System (Promus Element) for Coronary Revascularization in a Population of Unrestricted Patients
Background: A drug-eluting stent consists of 3 components of equal importance: a metallic platform, a polymer and a drug, all influencing acute and long term results both in safety and efficacy. The Platinum plus trial was designed to compare the Promus element stent to the Xience Prime. These stents have the same polymer poly (n butyl methacrylate) (PBMA) and poly (vinylidene fluoride co hexafluoropropylene) (PVDF-HFP)] and drug (Everolimus) but different platforms (platinum-chromium for the Promus element, cobalt chromium for the Xience prime) and distinct stent designs. Methods: Methods. The trial was designed as a non-inferiority single blind randomized 2:1 trial (Promus G1/XienceG2 that recruited 2985 consecutive, all-comer patients in 48 European centers. The primary endpoint was TVF at 1 year. Results: Results. Population consisted of 79% of males, mean age: 65 yrs Ϯ 9 yrs. Indications were 42 % stable angina 31.2% ACS and 10.2 % silent ischemia. Risk factors were well balanced between the 2 populations as follows: hypertension (65.8% vs. 68.1%, hypercholesterolemia (66.08% vs. 65.5%), diabetes I (3.5% vs. 4.07%), diabetes II (24.8 % vs. 22.4%), insulin-treated diabetes (7.4% vs. 6.8%), family history (32.4% vs. 23.3%), current smoker (20.4% vs. 19.9%). Procedural success was 98.4% in recipients of Promus stents and 97.8 % for Xience prime. Mean number of stents implanted per patient was 1.7 Ϯ0.8. In-hospital complications included death Nϭ3 and Nϭ1 (0.15 % and 0.10 %) for Promus and Xience, respectively, MI Nϭ7 (0.36%) and Nϭ2 (0.19%), emergency CABG Nϭ1 and Nϭ0 (0.05% and 0 %), repeat PCI (Nϭ4, Nϭ1). The observed differences were statistically not significant. Conclusions: Conclusion: No differences in acute results were observed between the 2 stents; the 30-day outcome will be available for the meeting.
TCT-614
Remote ischemic preconditioning improves outcome out to 6-years following elective percutaneous coronary intervention: the CRISP-Stent trial. Background: Remote ischemic preconditioning (rIPC) attenuates MI4a in humans undergoing elective percutaneous coronary intervention (PCI). However the long-term impact of rIPC on clinical outcomes after PCI is unknown. We hypothesized that rIPC attenuation of MI4a would improve clinical outcome at 6-years. Methods: We randomized 215 patients with normal cardiac troponin-I (cTnI Ͻ 0.04ng/mL), undergoing elective PCI to either rIPC (n ϭ 110): three 5-minute blood pressure cuff inflations to 200mmHg around the upper arm with 5-minutes of cuff deflation between, or control (n ϭ 105): a deflated cuff throughout, before PCI. Patients taking nicorandil or glibenclamide were excluded and randomization was stratified for diabetes mellitus (DM). Post-PCI serum cardiac troponin-I (cTnI) levels were recorded at 24-hours and major adverse cardiac and cerebral event (MACCE) rate determined at 6-years (90% follow-up, mean time to event or last follow-up: 1579.7 ϩ/Ϫ 603.6 days). Results: The two groups were matched demographically. Median 24-hour cTnI was significantly lower in the rIPC group (0.06 vs. 0.16ng/mL, pϭ0.04). Mean cTnI was higher in those with MACCE (0.91 vs. 2.07ng/mL, pϭ0.05). MACCE rate at 6-years was significantly lower in the rIPC group (23 vs. 36, pϭ0.039, Figure) . The non-DM subgroup (nϭ166) MACCE rate at 6-years was significantly lower following rIPC (17 vs. 29, pϭ0.045) but those with DM (nϭ49) did not derive benefit from rIPC (6 vs. 7, pϭ0.541).
Stephen
Conclusions:
Fewer patients receiving rIPC have post-PCI cTnI release and rIPC has a superior MACCE-free survival compared to control out to 6-years.
TCT-615
Coating Damage of Drug-Eluting Stent Occurs in Front Edge Strut: a Scanning Electron Microscopy Study
